Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or emergency department, and are less likely to utilize hospice ...
TAE Life Sciences (TLS), a leader in Boron Neutron Capture Therapy (BNCT), today announced the publication of new research in ACS Pharmacology & Translational Science (an ACS journal), demonstrating ...
Patients who receive aggressive anti-cancer treatments near the end of life are more likely to end up in the emergency department and less likely to elect hospice, according to a new study published ...
Dr. Van Morris presents the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma. Dr. Morris discusses the key recommendations from the Expert Panel, including ...
12d
Cancer risk rises with autoimmune disorders but drops after anti-inflammatory therapy, finds study
When patients start getting treated for conditions like psoriatic arthritis, or connective tissue diseases like lupus and ...
TAE Life Sciences announces breakthrough in boron neutron capture therapy research; shows durable tumour control and systemic immune effects: Foothill Ranch, California Friday, Ap ...
The MarketWatch News Department was not involved in the creation of this content. METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results